financetom
Business
financetom
/
Business
/
Elf Beauty projects annual sales, profit below estimates despite upbeat Q4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elf Beauty projects annual sales, profit below estimates despite upbeat Q4
May 22, 2024 1:35 PM

By Granth Vanaik

(Reuters) - Elf Beauty ( ELF ) projected annual sales and profit below Wall Street expectations on Wednesday, in a sign that sticky inflation has left little room for Americans to spend on affordable luxuries such as cosmetic and skincare products.

However, the California-based firm topped estimates for fourth-quarter revenue and profit.

WHY IT'S IMPORTANT

While beauty companies such as Elf managed to sustain the post-pandemic demand boom, the forecast indicates that still-high food prices and interest rates have forced customers to prioritize needs-based goods over discretionary purchases.

CONTEXT

Last month, retailer Ulta Beauty flagged a slowdown in demand across categories in the first quarter.

U.S. retail sales for cosmetics and beauty products are expected to grow by 6.9% in 2024, compared with 10.5% increase seen in 2023, according to data analytics firm Emarketer.

Analysts at UBS have also noted that Elf has a history of providing conservative full-year targets.

KEY QUOTE

"We do like to take things one quarter at a time ... it's very hard to kind of grow 80% on top of 80%," said CEO Tarang Amin in an interview with Reuters, adding that the first initial outlook is "very strong."

Amin also noted that Elf is seeing overall "good behavior" from a consumer standpoint.

BY THE NUMBERS

Elf expects 2025 sales to be between $1.23 billion and $1.25 billion, below expectations of about $1.27 billion, according to LSEG data.

The company expects annual adjusted profit to be between $3.20 and $3.25 per share, versus estimates of $3.51 apiece.

Net sales rose 71.4% to $321.1 million in the fourth quarter, beating estimates of about $292.6 million. In the previous quarter, sales grew by 84.9%.

It posted adjusted profit of 53 cents per share, topping expectations of 32 cents.

GRAPHIC

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Correction: --Iberdrola to Buy Remaining Stake in Avangrid for $2.55 Billion
Correction: --Iberdrola to Buy Remaining Stake in Avangrid for $2.55 Billion
May 17, 2024
11:51 AM EDT, 05/17/2024 (MT Newswires) -- (Corrects spelling of company name) ...
Update: Google DeepMind Announces Protocols to Identify Harmful AI Capabilities
Update: Google DeepMind Announces Protocols to Identify Harmful AI Capabilities
May 17, 2024
11:54 AM EDT, 05/17/2024 (MT Newswires) -- (Updates with additional details throughout.) Alphabet's (GOOG, GOOGL) Google DeepMind introduced its Frontier Safety Framework on Friday, a set of protocols to proactively identify future AI capabilities that could cause severe harm and mitigate them. While AI technology is set to revolutionize the way we solve critical global problems, from climate change to...
Salesforce's Seasonally Soft Q1 Offset by Bullish Outlook on GenAI Business, Morgan Stanley Says
Salesforce's Seasonally Soft Q1 Offset by Bullish Outlook on GenAI Business, Morgan Stanley Says
May 17, 2024
12:02 PM EDT, 05/17/2024 (MT Newswires) -- Salesforce ( CRM )' (CRM) upcoming fiscal Q1 results are unlikely to spur excitement as it is usually a seasonally soft quarter, and with foreign exchange headwinds and weak prints from front-office peers tempering expectations, Morgan Stanley said in a report Friday. But the firm said the near-term caution is being offset by...
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports
May 17, 2024
May 17 (Reuters) - Moderna ( MRNA ) has won a case at the European Patent Office in its dispute with Pfizer ( PFE ) and BioNTech over its COVID-19 vaccine, the Financial Times reported on Friday. Moderna ( MRNA ) did not immediately respond to a Reuters request for comment. (Reporting by Sriparna Roy in Bengaluru; Editing by Anil...
Copyright 2023-2026 - www.financetom.com All Rights Reserved